Published by Global Banking & Finance Review®
Posted on February 24, 2026
1 min readLast updated: April 2, 2026
Add as preferred source on GoogleAstraZeneca raised CEO Pascal Soriot’s 2025 pay 6.4% to £17.7m ($23.9m), driven by a £4.3m bonus up ~22% from 2024. The move keeps him among the FTSE 100’s top-paid chiefs as earnings improved.
Feb 24 (Reuters) - AstraZeneca Chief Executive Pascal Soriot's 2025 pay rose 6.4% to 17.7 million pounds ($23.87 million) boosted by higher annual bonuses, keeping him among the FTSE 100's highest-paid executives, a filing showed on Tuesday.
AstraZeneca, which is London's most valuable company and whose earnings jumped in 2025, paid Soriot 4.3 million pounds in annual bonus last year, up about 22% from 2024 levels, according to the company's annual report.
($1 = 0.7415 pounds)
(Reporting by Raechel Thankam Job in Bengaluru; Editing by Shailesh Kuber)
AstraZeneca increased CEO Pascal Soriot’s 2025 compensation to £17.7m ($23.9m), a 6.4% rise from the prior year. The boost was led by a larger annual bonus.
Soriot’s annual bonus reached £4.3m for 2025, about 22% higher than in 2024, contributing significantly to the overall pay increase.
The pay rise reflects AstraZeneca’s stronger 2025 performance and ongoing executive-compensation debates in the FTSE 100, which can influence governance and sentiment.
Explore more articles in the Finance category
